within Pharmacolibrary.Drugs.ATC.D;

model D10AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.08 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.1 / 1000000,
    adminCount     = 1,
    Vd             = 0.0005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Fluorometholone is a synthetic corticosteroid with anti-inflammatory properties, mainly used as an ophthalmic agent to treat inflammatory conditions of the eye, such as allergic conjunctivitis and postoperative inflammation. It is approved for use today in eye drops and ointments.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data for fluorometholone systemic exposure in humans appears to exist; pharmacokinetic parameters are estimated based on corticosteroid class and ophthalmic use.</p><h4>References</h4><ol><li><p>Baba, K, et al., &amp; Nishida, K (2021). The generation of fluorometholone nanocrystal eye drops, their metabolization to dihydrofluorometholone and penetration into rabbit eyes. <i>International journal of pharmaceutics</i> 592 120067–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2020.120067&quot;>10.1016/j.ijpharm.2020.120067</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33189813/&quot;>https://pubmed.ncbi.nlm.nih.gov/33189813</a></p></li><li><p>Lee, H, et al., &amp; Kim, SW (2023). Corticosteroid-Antibiotic Interactions in Bacteria that Cause Corneal Infection. <i>Translational vision science &amp; technology</i> 12(5) 16–None. DOI:<a href=&quot;https://doi.org/10.1167/tvst.12.5.16&quot;>10.1167/tvst.12.5.16</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37184498/&quot;>https://pubmed.ncbi.nlm.nih.gov/37184498</a></p></li><li><p>Schoenwald, RD, et al., &amp; Chien, DS (1987). Ophthalmic bioequivalence of steroid/antibiotic combination formulations. <i>Biopharmaceutics &amp; drug disposition</i> 8(6) 527–548. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2510080605&quot;>10.1002/bdd.2510080605</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3427210/&quot;>https://pubmed.ncbi.nlm.nih.gov/3427210</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D10AA01;
